GSK’s Dr Moncef Slaoui, Chairman, Vaccines, has indicated to the Board his intention to retire from the Company in 2017.
Dr Slaoui will remain a member of the Board until 31 March 2017. The Board supports Dr Slaoui’s decision and has agreed he will retire on 30 June 2017.
From 1 April 2017 until his retirement date, he will serve as an advisor to both GSK and the Board.
Dr Slaoui joined GSK in 1988 and the Board in 2006. Dr Slaoui’s move follows Chief Executive Officer Andrew Witty’s plan to leave his post in March after almost 10 years. Chairman Philip Hampton is currently heading the search for a new CEO as well as revamping GSK’s board after four directors chose not to stand for re-election this year.
Dr Slaoui previously served as the chairman of the drugmaker’s R&D for eight years. He oversaw the acquisition of Novartis AG’s vaccine division in 2015 in a complex three-part transaction. He is also credited with overhauling the company’s R&D as well as driving its vaccines pipeline.
Philip Hampton, Chairman, GSK, said: “GSK has been fortunate to benefit from Moncef’s considerable scientific and technical experience over many years and I’m pleased that during his remaining time, he will continue to provide this valuable expertise to the Company.”